Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, Maharashtra, India.
Pharm Biol. 2013 May;51(5):550-7. doi: 10.3109/13880209.2012.747547. Epub 2013 Feb 1.
Neuroprotective therapy to rescue dopaminergic neurons is an important trait in the management of Parkinson's disease (PD).
The present study identified and evaluated SFSE-T, a standardized hydroalcoholic extract of Trigonella foenum-graecum L. seeds (Fabaceae), in animal models of PD.
The identification of SFSE-T was carried out by high-performance liquid chromatography for the marker compound trigonelline (TGN). The effects of single dose oral treatment of SFSE-T (10, 30 or 100 mg/kg) were studied using animal models of PD, namely, 6-hydroxydopamine (6-OHDA)-induced unilateral lesions in rats, and 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurodegeneration in C57BL/6 mice. The effects of SFSE-T on monoamino oxidase (MAO) enzyme in vitro as well as possible side effects of SFSE-T in vivo were also evaluated.
The concentration of TGN in a test sample of SFSE-T was found to be 82%. SFSE-T (30 mg/kg, oral) showed a significant increase in the number of ipsilateral rotations (45.67 rotations in 30-min period) as compared with vehicle control group (no rotations) when tested in 6-OHDA-induced unilateral lesioned rats. SFSE-T (30 mg/kg, oral) showed significant reversal of motor dysfunction (spontaneous motor activity scores, speed, distance traveled and number of square crossed) caused by MPTP induced lesions in C57BL/6 mice in pretreatment (1 h) schedule but not in post-treatment (1 h) schedule. SFSE-T neither showed anticholinergic effects nor showed selective MAO-B enzyme inhibition in vitro.
SFSE-T showed reversal of motor symptoms in an animal model of PD probably through neuroprotective properties.
神经保护疗法以挽救多巴胺能神经元是治疗帕金森病（PD）的一个重要特征。
本研究鉴定并评价 SFSE-T，即甜三叶草种子（豆科）的标准化水醇提取物，在 PD 动物模型中的作用。
采用高效液相色谱法对 SFSE-T 中的标记化合物三乙胺（TGN）进行鉴定。通过 6-羟多巴胺（6-OHDA）诱导的大鼠单侧损伤模型和 4-苯基-1,2,3,6-四氢吡啶（MPTP）诱导的 C57BL/6 小鼠神经退行性变模型，研究 SFSE-T 单次口服治疗（10、30 或 100mg/kg）的作用。还评估了 SFSE-T 对单胺氧化酶（MAO）酶的体外作用以及 SFSE-T 体内可能产生的副作用。
SFSE-T 测试样品中的 TGN 浓度为 82%。SFSE-T（30mg/kg，口服）与载体对照组（无旋转）相比，在 6-OHDA 诱导的单侧损伤大鼠中，显著增加了同侧旋转的次数（30 分钟内 45.67 次旋转）。SFSE-T（30mg/kg，口服）在预处理（1 小时）方案中显著逆转了 MPTP 诱导的 C57BL/6 小鼠运动功能障碍（自发运动活动评分、速度、行驶距离和穿越方格数），但在后处理（1 小时）方案中则没有。SFSE-T 既没有显示出抗胆碱能作用，也没有在体外显示出对 MAO-B 酶的选择性抑制作用。
SFSE-T 可能通过神经保护作用逆转 PD 动物模型中的运动症状。
